A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
Public ClinicalTrials.gov record NCT03589326. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Study identification
- NCT ID
- NCT03589326
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Takeda
- Industry
- Enrollment
- 245 participants
Conditions and interventions
Interventions
- Cytarabine Drug
- Dexamethasone Drug
- Imatinib Drug
- Methotrexate Drug
- Ponatinib Drug
- Prednisone Drug
- Vincristine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 3, 2018
- Primary completion
- Aug 11, 2022
- Completion
- Jul 30, 2027
- Last update posted
- Nov 25, 2025
2018 – 2027
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| City of Hope - Duarte | Duarte | California | 91010 | — |
| University of California Los Angeles | Los Angeles | California | 90095 | — |
| Augusta University Georgia Cancer Center | Augusta | Georgia | 30912 | — |
| Indiana University | Indianapolis | Indiana | 46202 | — |
| Indiana Blood & Marrow Transplantation | Indianapolis | Indiana | 46237 | — |
| University of Kansas Medical Center Research Institute | Kansas City | Kansas | 66160 | — |
| University of Maryland Medical Center | Baltimore | Maryland | 21201 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Monter Cancer Center | New Hyde Park | New York | 11042 | — |
| Stony Brook University Medical Center | Stony Brook | New York | 11794 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Methodist Hospital | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 77 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03589326, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 25, 2025 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03589326 live on ClinicalTrials.gov.